Denmark· DK-28106751422
Tenkasi
A oritavancin product containing oritavancindiphosphat, registered in Denmark by Menarini International Operation Luxembourg S.A.. The same ATC class is registered in 12 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Oritavancin is registered in 12 of 19 countries.
Countries holding a registration under ATC J01XA05 (oritavancin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Oritavancin · ATC J01XA05
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Oritavancindiphosphat
- Manufacturer
- Menarini International Operation Luxembourg S.A.
- Country
- Denmark (DK)
- ATC code
- J01XA05
- ATC class
- Oritavancin
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106751422
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
68 interactions on record for oritavancin.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Oritavancin · interactions on record
68 records
- 2 severe
- 64 moderate
- 2 minor
Most severe, free to view
- HeparinB01AB01severe
- HeparinB05CX05severe
- Sodium picosulfateA06AB08moderate
- NitisinoneA16AX04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01XA05
Oritavancin, as other registers publish it.
- United StatesKimyrsaMelinta Therapeutics, LLC
- United StatesOrbactivMelinta Therapeutics, LLC
- United StatesOrbactivMelinta Therapeutics, LLC
- FinlandTenkasiMenarini International Operations Luxembourg S.A.
- PolandTenkasiMenarini International Operations Luxembourg S.A.
- PolandTenkasiMenarini International Operations Luxembourg S.A.
- FinlandTenkasiMenarini International Operations Luxembourg S.A.
- IcelandTenkasiMenarini International Operations Luxembourg S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8122e80a-6054-46e1-91f7-52d275de2d72 GET /v1/drugs/8122e80a-6054-46e1-91f7-52d275de2d72?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "1200 mg",
"auth_role": "MOD",
"dk_drugid": "28106751422",
"substance": "Oritavancindiphosphat",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "45184"
}See everything about oritavancin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.